G protein receptor kinase type 2: A novel target in cardiovascular drug development
In spite of significant advancement in pharmacotherapy, heart failure remains one of the main causes of death worldwide. The existing treatment of heart failure prolongs life span by slowing down the pathological process but does not induce heart healing. The β adrenergic receptor dysfunction is a h...
Main Authors: | Vasić Marko S., Japundžić-Žigon Nina M. |
---|---|
Format: | Article |
Language: | English |
Published: |
Srpsko lekarsko drustvo
2014-01-01
|
Series: | Hospital Pharmacology |
Subjects: | |
Online Access: | http://scindeks-clanci.ceon.rs/data/pdf/2334-9492/2014/2334-94921402109V.pdf |
Similar Items
-
Therapeutic Targets for Treatment of Heart Failure: Focus on GRKs and β-Arrestins Affecting βAR Signaling
by: Supachoke Mangmool, et al.
Published: (2018-11-01) -
β-Adrenergic receptor signaling in cardiac function and heart failure
by: Aasakiran Madamanchi
Published: (2020-12-01) -
Aldosterone Jeopardizes Myocardial Insulin and β-Adrenergic Receptor Signaling via G Protein-Coupled Receptor Kinase 2
by: Alessandro Cannavo, et al.
Published: (2019-08-01) -
β-adrenergic receptor responsiveness in aging heart and clinical implications
by: Nicola eFerrara, et al.
Published: (2014-01-01) -
Targeting cardiac beta-adrenergic signaling via GRK2 inhibition for heart failure therapy
by: Alessandro eCannavo, et al.
Published: (2013-09-01)